Pharmacokinetic and pharmacodynamic assessment of histamine H3 receptor occupancy by enerisant: a human PET study with a novel H3 binding ligand, [11C]TASP457

[1]  S. Chaki,et al.  A Novel Potent and Selective Histamine H3 Receptor Antagonist Enerisant: In Vitro Profiles, In Vivo Receptor Occupancy, and Wake-Promoting and Procognitive Effects in Rodents , 2020, The Journal of Pharmacology and Experimental Therapeutics.

[2]  P. Di Ciano,et al.  Exploring occupancy of the histamine H3 receptor by pitolisant in humans using PET , 2020, British journal of pharmacology.

[3]  Maryam Hamzeh-Mivehroud,et al.  Histamine H3 receptor antagonists/inverse agonists: Where do they go? , 2019, Pharmacology & therapeutics.

[4]  J. Pépin,et al.  Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study , 2019, Sleep.

[5]  Ming-Rong Zhang,et al.  Radiosynthesis and quality control of [11C]TASP457 as a clinically useful PET ligand for imaging of histamine H3 receptors in human brain. , 2016, Nuclear medicine and biology.

[6]  B. Gulyás,et al.  Guidelines to PET measurements of the target occupancy in the brain for drug development , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  Ming-Rong Zhang,et al.  [11C]TASP457, a novel PET ligand for histamine H3 receptors in human brain , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  T. Suhara,et al.  Development of TASP0410457 (TASP457), a novel dihydroquinolinone derivative as a PET radioligand for central histamine H3 receptors , 2016, EJNMMI Research.

[9]  Sandra M. Sanabria-Bohórquez,et al.  11C-MK-8278 PET as a Tool for Pharmacodynamic Brain Occupancy of Histamine 3 Receptor Inverse Agonists , 2014, The Journal of Nuclear Medicine.

[10]  C. Halldin,et al.  AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects. , 2013, The international journal of neuropsychopharmacology.

[11]  Mark Slifstein,et al.  Measuring Drug Occupancy in the Absence of a Reference Region: The Lassen Plot Re-Visited , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[12]  K. Browman,et al.  The histamine H3 receptor: an attractive target for the treatment of cognitive disorders , 2008, British journal of pharmacology.

[13]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  Karl J. Friston,et al.  Unified segmentation , 2005, NeuroImage.

[15]  Robert B. Innis,et al.  Strategies to Improve Neuroreceptor Parameter Estimation by Linear Regression Analysis , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[16]  L. Sheiner,et al.  Understanding the Dose-Effect Relationship , 1981, Clinical pharmacokinetics.

[17]  H. Akaike.  A new look at the statistical model identification , 1974 .

[18]  D. Campbell.  The use of kinetic-dynamic interactions in the evaluation of drugs , 2005, Psychopharmacology.